The loss of mitochondrial function has been implicated in a number of maladies such as Huntington's Disease, Parkinson's Disease, cancer and cardiovascular disease. The objective of this research was to develop a radiolabeled mitochondrial probe. Two tracers, 7´-Z-iodorotenol and 7´-Z-iodorotenone, analogs of rotenone a natural product that inhibits Complex I of the mitochondrial electron transport chain, have been labeled with iodine-125 in 45-85% yield in a single step from the corresponding tribuytylstannyl precursor. In vivo distribution in adult male Sprague-Dawley rats for both compounds showed high accumulation in the heart (1.7-3.7 %ID/g at 1h), a tissue with high mitochondrial content. Z-Iodorotenol did not washout of most tissues between 1 and 2 h post injection whereas Z-iodorotenone showed moderate washout (7-26%) over the same period. By 24 h there was significant loss of both compounds from most tissues including the heart. Heart-to-blood, -lung and -liver ratios for Z-iodorotenone of 28.9, 10.7 and 2.4, respectively, were two-to four-fold higher than the Z-iodorotenol ratios. Compared to the current clinical perfusion tracers, Tc-tetrofosmin, Z-iodorotenone demonstrates similar 1h heart accumulation and significantly higher heart-to-lung ratio (P <0.001). Z-Iodorotenone heart-to-liver ratio is equivalent to 99m Tc-sestamibi. 7´-Z-Iodorotenone possesses distribution characteristics of an improved tracer for SPECT perfusion studies.
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Introduction
Mitochondrial dysfunction has been linked to normal aging processes as well as a variety of diseases including neurodegeneration (Alzheimer's, Huntingon's and Parkinson's diseases) [1] , cancer, osteoarthritis and cardiovascular disease. Wallace and colleagues have gathered evidence supporting a unified threshold hypothesis [2] . Wallace posits that each individual is born with a given mitochondrial mass. As one ages mutations to the mitochondrial DNA (mtDNA) diminishes the mitochondrial energy capacity. Organ failure or disease may ensue if the mitochondrial capacity falls below a certain threshold in a given organ system. Normal aging is defined under this hypothesis as a slow loss of energy capacity over ones lifetime ultimately leading to progressive system failure. Mitochondrial-related disease is characterized by either an inherited genetic defect that significantly lowers the initial amount of mitochondria or environmental factors such as oxidative damage to mtDNA that speeds up the energy capacity loss as postulated in the case of Parkinson's Disease [3, 4] .
Rotenone (1, Figure 1 ), a natural product found in the roots of the tropical Derris plant, has been shown to be a potent reversible inhibitor (IC 50 = 0.25 nM) of Complex I of the mitochondrial electron transport chain [5] . Rotenone and preparation of crude root extracts have been widely used as "organic" insecticides and piscicides, due to their biological activity and rapid breakdown to environmentally benign byproducts [6, 7] . Several rotenonids have been isotopically labeled with 13 C, 14 C, 2 H and 3 H for structural studies [8] and to assess Complex I activity in vivo and in particular the loss of Complex I related to Parkinson's Disease (PD) [9] .
Tritiated (6',7')-dihydrorotenone [10] has been used to determine the regional distribution of Complex I in rodent brain [11, 12] as well as to assess binding to intact human platelets as a potential biomarker of PD [13] .
Positron labeled analogs have been developed and evaluated as prospective in vivo imaging probes of Complex I activity. The brain distribution of two carbon-11 labeled radiotracers, (2-[ 11 C]methoxy)rotenone and (2-[ 11 C]methoxy)-6´,7´-dihydroroten-12-ol, were evaluated in balb/c female mice [14, 15] . The regional distribution in the mouse brain was relatively equivalent with the overall brain uptake of the rotenol being higher than that of the rotenone. Further assessment of the [ 11 C]dihydrorotenol in unilateral intrastriatal quinolinic acid and MPP+ lesioned rats demonstrated the in vivo sensitivity of the tracer to the loss of Complex I in the striatum [16, 17] .
Fluorine-18 labeled rotenone analogs, 6',7'-dihydro-7'-fluororotenone and 12-deoxy-6',7'-dihydro-7'-fluororotenone, have been produced and evaluated in rats. Both compounds exhibited rapid clearance from the blood accompanied by early uptake in the brain and heart [18] [19] [20] . The 12-deoxy compound cleared from brain and heart indicative of its reduced Complex I affinity.
While several of these tracers possess suitable imaging characteristics, the Complex I imaging capabilities of these tracers has yet to be fully exploited.
Ongoing studies in our laboratory have corroborated the heart uptake seen in the Emory studies [18] and have demonstrated the avidity of the labeled rotenone analogs for the heart. Tc-sestamibi, a tracer that accumulates in the heart tissue based on the mitochondrial membrane potential. [23, 24] It is not surprising that the rotenone analogs accumulate in the heart tissue given that mitochondria represent 20-30% of the myocardial mass. [25] Thus, given their distribution and biologic properties labeled rotenones represent a new class of potential cardiac perfusion tracers.
The detailed syntheses of two radioiodinated rotenone analogs, 7'-(Z)-iodorotenol (4, Scheme 1) and 7'-(Z)-iodorotenone (5, Scheme 1), are reported herein. The corresponding iodine-125 labeled derivatives were prepared by iododestannylation of the tributylstannane intermediates.
Additionally, the biological distribution of both radiotracers was evaluated in normal SpragueDawley rats. 
Materials and methods

General
7'-(Z)-Iodorotenol (4)
To a suspension of Ph 3 PCH 2 I 2 (6.0 g, 11.3 mmol) in THF (20 mL) was added NaN(TMS) 2 (11.5 mL, 1.0 M solution in THF, 11.5 mmol). Upon dissolution, the flask was cooled to -78 o C and HMPA (3 mL) was added. Oxo-rotenol 3 (3.7 g, 9.3 mmol) in THF (10 mL) was added slowly, and the solution was allowed to warm to room temperature. The solution was diluted with water and extracted with CH 2 Cl 2 . The combined extracts were washed with aqueous ( 
7'-(Z)-Iodorotenone
7'-(Z)-Tributylstannylrotenone (7)
To a solution of tributylstannylrotenol 6 (75 mg, 0.11 mmol) in CH 3 CN (10 mL) was added MeOH/ H 2 O -triethylammonium phosphate pH 7.4, 2 mL/min, t R = 6.0 min). The product was stored in ethanol at -80 o C in a sealed vial.
7'-(Z)-[
In Vivo Biodistribution Studies
All animal experiments were carried out in compliance with the Guidelines for Care and Use anesthesia. Blood and organs were removed, weighed and assayed for radioactivity using a Packard Gamma Counter. The percent injected dose per gram of tissue was determined.
Results
Synthesis of Iodorotenol, Iodorotenone and the corresponding tributylstannyl precursors
The synthetic pathway for the preparation of iodorotenol 4 and iodorotenone 5 is shown in Oxidation of the 12 hydroxy group of Z-iodorotenol 4 gave Z-iodorotenone 5 in one minute using activated manganese dioxide. Typical yields for this reaction ranged from 25-58% with recovery of a significant amount (~25%) of starting iodorotenol and a by-product. When the oxidation time was increased to five minutes the starting material was completely consumed, however, the Z-iodorotenone yield decreased significantly with a concomitant increase in the by-product. The overall yield of Z-iodorotenone for the four-step conversion from rotenone was 5-11%.
The synthesis of the vinyl stannane labeling precursors from the common intermediate iodorotenol 4 is shown in Scheme 2. Reaction of Z-iodorotenol 4 with hexabutylditin using catalytic tetrakis(triphenylphosphine)-palladium (0) gave the 7'-(Z)-tributylstannylrotenol 6 in low yield (10-15%). Subsequent oxidation of 6 to the corresponding 7'-(Z)-tributylstannylrotenone 7 was accomplished with manganese dioxide. The constraints of the oxidation reaction are the same as previously described for the conversion of 4 to 5 and account for the moderate oxidation yield of 40%. The overall yield of the stannylrotenol 6 and the stannylrotenone 7 from starting rotenone is 1.8% and 0.7%, respectively.
Synthesis of radioiodinated iodorotenone and iodorotenol
The radioiodination reactions are shown in Scheme 2. 
In Vivo Biodistribution Studies
The distribution of the radioiodinated rotenone analogs at 1h, 2h and 24h was evaluated in ~200 gram male Sprague-Dawley rats. The tissue biodistribution of 7'-(Z)-[ 125 I]iodorotenol 8 is presented in Table 1 and that of 7'-(Z)-[ 125 I]iodorotenone 9 in Table 2 . Both compounds were rapidly taken up in the heart (1.7 %ID/g for 8 and 3.7%ID/g for 9). The initial amount of tracer that remained in the blood was inversely proportional to the heart uptake with the Z-iodorotenol
8 blood values nearly double that of the Z-iodorotenone 9. The 1h uptake in the rest of the tissues was comparable for both compounds. Interestingly, there is considerable uptake of the tracer in the brain for both compounds during the first hour.
The distribution of Z-iodorotenol 8 does not significantly change in most tissues between 1 h and 2 h post injection, with the exception of the kidneys and brain (P < 0.02), yet by 24h there is significant washout (43-92%) from all tissues with the exception of the thyroid. Z-Iodorotenone 9 shows significant moderate (7-26%; P < 0.03) washout by 2 h from all tissues except for blood, lung, muscle, thyroid and fat. By 24 h there is significant loss of tracer (53-89%) from all tissues with the exception of thyroid and fat.
The rate of in vivo deiodination as evidenced by the percent injected dose in the thyroid is comparable for both compounds. The calculated linear thyroid accumulation rate appears to be about 0.15-0.2% per hour over the first 24 h. The rats were not pretreated with potassium chloride to block radioiodide uptake in the thyroid tissue.
Heart-to-tissue ratios were calculated for the blood, lung and liver. These values are given for Z-iodorotenol 8 and Z-iodorotenone 9 in Tables 1 and 2 , respectively. The heart-to-blood ratio was the highest at the 1 h time point for each compound with the Z-iodorotenone ratio being four-fold higher than the Z-iodorotenol (28.9 compared to 6.6). The heart-to-blood ratios for both compounds decreased significantly (P < 0.03) at each time point up to the end of the study at 24 h post injection. The heart-to-lung ratio was again highest at 1 h post injection for both tracers (3.1 for 8 and 10.7 for 9). There was no significant change in the ratio for either tracer between 1 and 2 hours. By 24 h the heart-to-lung ratio for Z-iodorotenone dropped by nearly 43% to 6.1 while there was no change in the ratio (3.1-3.2) for the Z-iodorotenol over the entire study period. The 1 h heart-to-liver ratio for Z-iodorotenol was just over 1. It remained unchanged at 2h but increased to 1.8 between 2h and 24h. Z-Iodorotenone heart-to-liver ratios remained around 2.4 throughout the course of the study.
Discussion
The two iodinated rotenoids were synthesized in good yield from commercially available rotenone in three to four steps. All of the reactions gave predominantly the desired products with the exception of the manganese dioxide mediated oxidation of the rotenols to rotenones. Based on our work with the fluororotenones and literature precedence [27, 28] the major by-product of the oxidation was identified as the 6a-12a unsaturated compound. The oxidation of the iodorotenone to the 6a-12a dehydro-iodorotenone competes with the conversion of iodorotenol to iodorotenone. Thus, optimizing the reaction time and amount of manganese dioxide is critical for suitable yields of the iodorotenone.
As with the manganese dioxide oxidations, unavoidable oxidation by the peracetic acid during the radiochemical reactions may be impacting the Z- or alternative oxidants was not undertaken for the iodorotenone reaction, increasing the reaction time prior to quenching decreased the iodorotenone to by-product ratio. It is known from our work with the rotenoids (unpublished data) that a variety of other oxidizing agents did not improve the overall yield nor the desired rotenone-to-byproduct ratio.
An optimal cardiac flow tracer possesses the following characteristics, rapid and high extraction from the blood into the heart tissue, good retention in the cardiac tissue, linear uptake with flow at all flow rates, high heart-to-blood, high heart-to-lung and high heart-to-liver ratios as well as suitable clearance from liver and kidneys. There has been considerable effort to produce an ideal technetium-99m labeled tracer for SPECT perfusion imaging that surpass the less than ideal characteristics of the current clinical tracers, [ retention of the tracers is not captured in the present biodistribution study, Z-iodorotenone has been shown to have high first pass extraction (~84%) and better retention versus sestamibi (~48% first pass extraction) in isolated perfused rabbit heart studies. [21] The rodent biodistribution model does show tracer accumulation in the heart but is unable to discriminate the differences in extraction and retention that are important for selecting improved perfusion tracers. More sophisticated models of perfusion, such as the isolated perfused rabbit heart model, are necessary to examine the flow characteristics.
Both Z-iodorotenol and Z-iodorotenone are retained in the heart tissue from 1-2 h but ~85%
of the activity washes out of the heart tissue from 2 to 24 h. Without a gold standard it is difficult to evaluate the relative retention of these tracers in the intact rodent model. However, in the isolated perfused rabbit heart studies iodorotenone is retained in the heart to a greater extent than The uptake in the tissues surrounding the heart, most notably the lungs, define the contrast value of the tracer as a cardiac perfusion imaging agent. The crown of the liver also appears in the images near the heart so it is desirable to have a high heart-to-liver ratio in addition to a high heart-to lung ratio. The 1 h heart-to-lung and heart-to-liver ratios for Z- Figure 4 . While the absolute heart uptake of iodorotenone was similar to sestamibi and tetrofosmin, Z-iodorotenone demonstrated significantly superior (P < 0.001) heart-to-lung ratios in the rodent at 1 h post injection. This contrast was sustained out to 2 h post injection. The heart-to-liver ratio for iodorotenone was equivalent to that of [ respective tributylstannyl precursors. The good heart uptake combined with the high heart-toblood and heart-to-lung ratios and good clearance from the kidneys demonstrates the favorable distribution characteristics of iodorotenone. Combined with the studies conducted in the isolated perfused rabbit heart, iodorotenone possesses desirable properties of an improved cardiac flow tracer that may prove valuable as a more sensitive identifier of significant coronary lesions.
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